Get the Stockscreener App
2.1455
4.15%
0.0855
After Hours:
2.06
-0.0855
-3.99%
Avenue Therapeutics Inc stock is traded at $2.1455, with a volume of 15,725.
It is up +4.15% in the last 24 hours and down -12.43% over the past month.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
See More
Previous Close:
$2.06
Open:
$2.0526
24h Volume:
15,725
Relative Volume:
0.36
Market Cap:
$4.10M
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.4287
EPS:
-5.0046
Net Cash Flow:
$-12.45M
1W Performance:
+6.74%
1M Performance:
-12.43%
6M Performance:
-42.48%
1Y Performance:
-83.60%
1-Day Range:
$2.02
$2.1455
1-Week Range:
$2.002
$2.15
52-Week Range:
$1.60
$26.47
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare ATXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
2.1455 | 4.10M | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Avenue Therapeutics Inc Stock (ATXI) Latest News
Avenue Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Avenue Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Nigeria
Avenue Therapeutics stock hits 52-week low at $1.68 - Investing.com
Avenue Therapeutics Inc (ATXI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires Additional Shares in Avenue Ther - GuruFocus.com
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Canadian North Resources Inc. Announces Appointment Of Henderson Tse To The Board Of Directors - The Manila Times
Avenue Therapeutics Reports $3.1M Q3 Loss, Advances Key Clinical Trials Pipeline | ATXI Stock News - StockTitan
Expedia faces threat from tepid growth in 2025, Deutsche Bank says after downgrade - Investing.com
Avenue Therapeutics director Jay Kranzler sells $136 in stock - Investing.com India
Avenue Therapeutics director Jay Kranzler sells $136 in stock By Investing.com - Investing.com UK
APLT (Applied Therapeutics) Cash From Other Investing Activities : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Drug Resistant Epilepsy Market Size, Industry Analysis, - openPR
Mustang Bio, Inc. Appoints David Jin as A Member of the Board - Marketscreener.com
NYC officials envision turning Fifth Avenue into a grand boulevard | Company Business News - Mint
Avenue Therapeutics stock hits 52-week low at $1.89 By Investing.com - Investing.com Australia
Avenue Therapeutics stock hits 52-week low at $1.89 - Investing.com
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - Business Wire
DMart Q2 Results: Avenue Supermarts net profit rises 5.77% to ₹659.58 crore, revenue up 14.41% YoY | Company Business News - Mint
IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Park Avenue Securities LLC - Defense World
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit - GlobeNewswire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. - GlobeNewswire
Avenue Therapeutics stock hits 52-week low at $2.17 By Investing.com - Investing.com South Africa
Avenue Therapeutics stock hits 52-week low at $2.17 - Investing.com
Avenue Therapeutics director buys shares worth $1,249 By Investing.com - Investing.com South Africa
Avenue Therapeutics director buys shares worth $1,249 - Investing.com India
Frazier Life Sciences Management L.P. Increases Stock Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Avenue Therapeutics grants stock units to top executives By Investing.com - Investing.com Canada
Avenue Therapeutics grants stock units to top executives - Investing.com India
Avenue Therapeutics Incentive Plan Awards Key Executives - TipRanks
FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Avenue Therapeutics stock hits 52-week low at $2.23 By Investing.com - Investing.com Canada
Avenue Therapeutics stock hits 52-week low at $2.23 - Investing.com
Avenue Supermart shares rise 1.49% as Sensex climbs - The Economic Times
Avenue Supermart rises 1.49% as Sensex climbs - The Economic Times
Share price of Avenue Supermart falls as Sensex gains 251.05 points - The Economic Times
Victory Capital Management Inc. Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Forest Avenue Capital Management LP Has $44.92 Million Position in Walmart Inc. (NYSE:WMT) - Defense World
Postoperative acute pain Market Size is Set for Rapid Growth as - openPR
Forest Avenue Capital Management LP Has $24.54 Million Holdings in GE Vernova Inc. (NYSE:GEV) - Defense World
Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM
Amplia Therapeutics’ Drug Fast-Tracked by FDA - TipRanks
First Avenue IPO on Nomu 740% oversubscribed; offer price set at SAR 6 - بوابة أرقام المالية
Avenue Supermart shares down 0.27% as Nifty gains - The Economic Times
Avenue Supermart shares fall 0.27 per cent in Thursday's trading session - The Economic Times
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - AccessWire
Avenue Supermart shares up 0.35% as Nifty gains - The Economic Times
SEC Form S-3 filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
2 Dead In Series Of Police Shootouts That Shut Down Victory Boulevard - Patch
Meet Microsoft’s new COO—a former superstar CFO from GE - Fortune
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):